1. Academic Validation
  2. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy

Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy

  • J Control Release. 2021 Jan 10;329:445-453. doi: 10.1016/j.jconrel.2020.11.064.
Qingle Ma 1 Qin Fan 1 Xiao Han 1 Ziliang Dong 1 Jialu Xu 1 Jinyu Bai 2 Weiwei Tao 3 Dongdong Sun 4 Chao Wang 5
Affiliations

Affiliations

  • 1 Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, China.
  • 2 The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
  • 3 School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
  • 4 School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, PR China; Collaborative Innovation Center of Jiangsu Province of Cancer Prevention and Treatment of Chinese Medicine, Nanjing 210023, PR China. Electronic address: [email protected].
  • 5 Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, China. Electronic address: [email protected].
Abstract

Atherosclerosis is a kind of chronic inflammatory diseases characterized by dysfunction of local immune responses. Here we engineer platelet-derived extracellular vesicles (PEVs) to load MCC950, an NLRP3-inflammasome inhibitor, for atherosclerosis-targeted therapy. PEVs which are readily collected from the activated platelets selectively bind multiple cell types associated with the formation of atherosclerotic plaque in vivo. Intravenous administration of MCC950-PEVs could significantly reduce the formation of atherosclerotic plaques, lower the local inflammation and inhibit proliferation of macrophages and T cells at the plaque site compared with free drug administration in ApoE-KO mice. Our strategy suggests the promise of PEVs for targeted drug delivery for treatment of atherosclerosis.

Keywords

Anti-inflammation; Atherosclerosis; Immunotherapy; Platelet-derived extracellular vesicles; Targeting delivery.

Figures
Products